Home / Themes / Infra Built in ZIRP '25: HC Platforms
Infra Built in ZIRP '25: HC Platforms (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 1 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsAs of Spring 2025, the investment thesis for the "Infra Built in ZIRP: HC Platforms" subtheme, including GH (Guardant Health) and EXAS (Exact Sciences), is bull
Thesis
As of Spring 2025, the investment thesis for the "Infra Built in ZIRP: HC Platforms" subtheme, including GH (Guardant Health) and EXAS (Exact Sciences), is bullish. These companies have leveraged the infrastructure and technological advancements made during the era of zero interest rate policy (ZIRP) to establish strong operational moats in the healthcare diagnostics sector. This foundational strength allows them to capitalize on the growing demand for innovative cancer screening and diagnostics in a post-ZIRP environment, positioning them well for sustained growth.
Bull case
Both GH and EXAS have developed extensive technological platforms and data networks during the ZIRP era, which are now yielding efficiencies and cost advantages over competitors.
The shift towards personalized medicine and early cancer detection is driving increased demand for advanced diagnostic solutions, favoring companies with established infrastructures like GH and EXAS.
These companies are reporting strong financial performance, with revenue growth and profitability exceeding pre-pandemic levels, indicating successful adaptation to the current market environment.
Bear case
The transition from ZIRP to a higher interest rate environment increases borrowing costs, potentially impacting future R&D investments and growth initiatives for GH and EXAS.
Competition in the healthcare diagnostics space is intensifying, with new entrants potentially challenging the incumbents' market share and pricing power.
Regulatory changes and reimbursement rates could adversely affect the profitability of diagnostic tests, posing a risk to companies heavily reliant on such revenue streams.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Test Volume & ASP | Quarterly | Most direct read on adoption and pricing power. Volume + stable or rising ASP = platform scaling well. | Google_Sheets |
| Gross Margin on Testing | Quarterly | Tracks lab efficiency and pricing strength. Should expand as scale increases and fixed lab costs get absorbed. | Google_Sheets |
| CMS reimbursement updates | Real-time | Understanding policy environment | Google_Sheets |
Upcoming Catalysts
No data for this section.
Constituents
- GHT2— Guardant Health, Inc.
- EXAST2· no notes yet
- DOCST3· no notes yet
- GDRXT3· no notes yet
- OPRXT3· no notes yet
- VEEVT3· no notes yet